Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study

Keyphrases

• Adrenal Function 100%
• Functional Recovery 100%
• Oral Corticosteroids 100%
• Corticosteroid-sparing 100%
• Benralizumab 100%
• Corticosteroids 66%
• Maintenance Phase 50%
• Adverse Events 33%
• Median Range 33%
• Asthma Exacerbation 33%
• Daily Dose 33%
• Asthma Control 33%
• St. George's Respiratory Questionnaire 33%
• Adrenal Insufficiency 33%
• Asthma Control Questionnaire 33%
• 1-median 16%
• Quality of Life Improvement 16%
• Adverse Outcomes 16%
• Severe Eosinophilic Asthma 16%
• Corticosteroid Dependence 16%

Medicine and Dentistry

• Adrenal Function 100%
• Benralizumab 100%
• Asthma 75%
• Adverse Event 50%
• Adrenal Insufficiency 50%
• St. George Respiratory Questionnaire 50%
• Asthma Control Questionnaire 50%
• Asthma Exacerbation 50%
• Quality of Life 25%
• Deterioration 25%
• Adverse Outcome 25%
• Eosinophilic 25%
• Drug Dose Increase 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Asthma 100%
• Benralizumab 100%
• Adverse Event 33%
• Adrenal Insufficiency 33%
• Deterioration 16%
• Adverse Outcome 16%
• Asthmatic State 16%